Centessa Pharmaceuticals plc ADR [CNTA] stock is trading at $18.08, up 6.35%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CNTA shares have gain 13.07% over the last week, with a monthly amount glided 12.37%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on September 20, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $26 from $11. Previously, B. Riley Securities started tracking the stock with Buy rating on September 19, 2024, and set its price target to $33. On July 18, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $14 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $8 on October 26, 2023. In a note dated June 12, 2023, Guggenheim initiated an Buy rating and provided a target price of $9 on this stock.
Centessa Pharmaceuticals plc ADR [CNTA] stock has fluctuated between $5.58 and $17.79 over the past year. Currently, Wall Street analysts expect the stock to reach $21.67 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $18.08 at the most recent close of the market. An investor can expect a potential return of 19.86% based on the average CNTA price forecast.
Analyzing the CNTA fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.29 points at the first support level, and at 16.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.81, and for the 2nd resistance point, it is at 19.53.
Ratios To Look Out For
For context, Centessa Pharmaceuticals plc ADR’s Current Ratio is 21.52. As well, the Quick Ratio is 21.52, while the Cash Ratio is 14.96. Considering the valuation of this stock, the price to sales ratio is 296.14, the price to book ratio is 4.77.
Transactions by insiders
Recent insider trading involved SAHA SAURABH, Officer, that happened on Nov 13 ’24 when 32023.0 shares were purchased. Chief Business Officer, Weinhoff Gregory M completed a deal on Oct 25 ’24 to sell 11742.0 shares. Meanwhile, Officer Weinhoff Gregory M bought 11742.0 shares on Oct 25 ’24.
